FINWIRES · TerminalLIVE
FINWIRES

AstraZeneca Pharma India Gets India Approval to Use Enhertu in Breast Cancer Treatment

By

AstraZeneca Pharma India (NSE:ASTRAZEN, BOM:506820) has received permission from India's Central Drugs Standard Control Organization to import and distribute Enhertu (trastuzumab deruxtecan) for an additional breast cancer indication, according to a Thursday filing.

The approval allows the drug, in combination with pertuzumab, to be used for first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, the filing said.

AstraZeneca Pharma shares were down nearly 1% in after-market hours.

Related Articles

Asia

Kim Forest Enterprise Wins NT$110 Million Genome Sequencing Kit Supply Deal

Kim Forest Enterprise (TPE:6645) won a tender to supply whole genome sequencing assay kits to a national hospital in Taiwan under a contract worth NT$110 million, according to a Wednesday Taiwan Exchange filing.Shares slid about 2% in Thursday's late morning trade.The contract runs from June 10, 2026, to Dec. 31, 2028.Kim Forest said the deal is expected to expand its business operations and boost revenue.

TPE:6645
Asia

Beijing Balance Medical Tech to Buy Back Up to 100 Million Yuan Worth of Shares

Beijing Balance Medical Technology (SHA:688198) plans to repurchase shares worth between 50 million yuan and 100 million yuan, according to a Shanghai bourse filing on Thursday.The company will buy back between 359,583 shares and 719,165 shares, which represents 0.26% to 0.52% of the company's total shares, within 12 months after the approval of the board of directors.The maximum repurchase price will be 139.05 yuan per share.The repurchased shares will be used for the company's employee stock ownership plan or equity incentives.The medical device manufacturer's shares rose 1% during the morning trade.

SHA:688198
Asia

MediaTek's Sales Edge Up in April; Shares Drop 3%

MediaTek (TPE:2454) booked consolidated net sales of NT$47.4 billion in May, up 1.5% from NT$46.7 billion in April, according to a Wednesday Taiwan Exchange filing.Shares slid about 3% in Thursday's late morning trade.MediaTek did not provide further details in the filing.

TPE:2454